Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
miR-200b is a tumor suppressor in multiple tumors including gastric cancer, breast cancer, ovarian cancer and
glioma
. In this study, we detected the expression of miR-200b and analyzed its correlation with clinicopathological parameters in
glioma
tissues. miR-200b was downregulated in
glioma
tissues. And its downexpression was correlated with poor prognosis in gliomas. Members of RAB family,
RAB21
, RAB23, RAB18 and RAB3B were predicted to be novel targets of miR-200b. The direct suppression of
RAB21
, RAB23, RAB18 and RAB3B expressions by miR-200b was revealed by luciferase reporter assay, quantitative RT-PCR analysis and Western blot. Furthermore, the overall survival of patients with different expression of RABs was analyzed. The expression of
RAB21
, RAB23, RAB18 and RAB3B was related to the prognosis and histopathology of
glioma
. The patients who had the upregulation of all the four RABs had the worst outcome; those who had the downregulation of all RABs had the best outcome (p<0.001). miR-200b was a potential biomarker for
glioma
prognosis.
...
PMID:miR-200b as a prognostic factor targets multiple members of RAB family in glioma. 2447 53